Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qutenza vs Duloxetine for Chemotherapy-induced Peripheral Neuropathy
NCT05560516Recruiting
- Sponsor
- University of Amsterdam
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of capsaicin 8% patch in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by University of Amsterdam. Primary endpoint: Numeric Rating Scale at 12 weeks. Started Dec 2022; status: recruiting.
02
Drugs
capsaicin 8% patch
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05560516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560516.